3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Prostatic Neoplasms
7
Lymphoma
5
Burkitt Lymphoma
5
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Leukemia
2
Endometrial Neoplasms
2
Down Syndrome
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphoma, T-Cell, Peripheral
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Heart Failure
1
Enteropathy-Associated T-Cell Lymphoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
rozanolixizumab
8
zilucoplan
7
ravulizumab
6
fludarabine
5
efgartigimod alfa
5
Cyclophosphamide
5
telitacicept
3
Prednisone
3
inebilizumab
2
Rituximab
2
Pyridostigmine Bromide
2
tofacitinib
1
thymoglobulin
1
talquetamab
1
remibrutinib
1
prednylidene
1
iptacopan
1
eculizumab
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Walk Test
1
Therapeutics
1
Tacrolimus
1
Steroids
1
Robotic Surgical Procedures
1
Psychodrama
1
Prednisolone
1
Plasma Exchange
1
Peripheral Blood Stem Cell Transplantation
1
Oxaloacetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Prednisolone
×
1 year
×
Clear all
NCT07221838
2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4
Recruiting
75 enrolled